Tags : Nasal Polyposis

Sanofi’s Dupixent (dupilumab) Receives the Health Canada Approval for Severe

Tuba Khan August 19, 2020

Shots: The Health Canada has approved a new indication as an add-on maintenance treatment with intranasal corticosteroids in patients with CRSwNP, inadequately controlled by systemic corticosteroids or surgery The approval […]readmore

Biotech Regulatory

Regeneron and Sanofi’s Dupixent (dupilumab) Receives FDA’s Approval for Chronic

Tuba Khan June 27, 2019

Shots: The approval is based on two SINUS-24 & SINUS-52 studies results assessing Dupixent (300mg, q2w) + mometasone furoate nasal spray (MFNS) vs PBO + MFNS in patients with CRSwNP […]readmore

Tags : Nasal Polyposis

Sanofi’s Dupixent (dupilumab) Receives the Health Canada Approval for Severe

Regeneron and Sanofi’s Dupixent (dupilumab) Receives FDA’s Approval for Chronic

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Nasal Polyposis

Sanofi’s Dupixent (dupilumab) Receives the Health Canada Approval for Severe

Regeneron and Sanofi’s Dupixent (dupilumab) Receives FDA’s Approval for Chronic

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company